Spire Wealth Management’s Day One Biopharmaceuticals DAWN Stock Holding History

Spire Wealth Management’s Portfolio DAWN Stock Details DAWN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-40	Closed	-$858	–	2262
2026 Q1	$858	Buy	+40	New	+$564	﹤0.01%	2170
2025 Q1	–	Sell	-40	Closed	-$507	–	2492
2024 Q4	$507	Hold	40	–	–	﹤0.01%	2437
2024 Q3	$557	Hold	40	–	–	﹤0.01%	2142
2024 Q2	$551	Hold	40	–	–	﹤0.01%	2186
2024 Q1	$661	Hold	40	–	–	﹤0.01%	2268
2023 Q4	$557	Buy	+40	New	+$485	﹤0.01%	2348
2023 Q2	–	Sell	-40	Closed	-$535	–	2421
2023 Q1	$535	Hold	40	–	–	﹤0.01%	2466
2022 Q4	$1K	Hold	40	–	–	﹤0.01%	2159
2022 Q3	$1K	Buy	+40	New	+$851	﹤0.01%	2056

Other funds holding DAWN

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Spire Wealth Management's DAWN Position: Q2 2026 in Review

Spire Wealth Management sold out of Day One Biopharmaceuticals (DAWN) in Q2 2026, closing a stake of 40 shares — an estimated $858 sold.

Spire Wealth Management first reported a position in DAWN in Q3 2022 and held it in 9 quarters. The position peaked at $1K in Q4 2022. 1 fund tracked by Wall St. Rank holds DAWN as of Q2 2026.

Spire Wealth Management reported no remaining Day One Biopharmaceuticals position as of Q2 2026 after selling out during the quarter.
Spire Wealth Management sold 40 Day One Biopharmaceuticals shares in Q2 2026, an estimated $858.
Spire Wealth Management first reported a position in Day One Biopharmaceuticals in Q3 2022 and held it in 9 quarters.
Spire Wealth Management's Day One Biopharmaceuticals position peaked at $1K in Q4 2022.
1 fund tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2026.

Based on Spire Wealth Management's 13F filing for Q2 2026, filed 15 Jul 2026.